Clover Health (CLOV) Is Up 14.1% After Raising 2026 Profit Outlook And Returning To Net Income

• Clover Health Investments, Corp. reported second-quarter 2026 results showing net income of US$28 million versus a US$10.58 million loss a year earlier, with basic and diluted earnings per share from continuing operations improving to US$0.05 from a US$0.02 loss.
• For the first half of 2026, Clover Health generated US$55.34 million in net income and, on the same day, raised its full-year 2026 revenue and GAAP net income guidance, signaling materially higher expectations for both top-line and profitability than previously indicated.
• Next, we'll examine how Clover Health's move to raise full-year revenue and GAAP net income guidance influences its existing investment narrative.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free.

Clover Health Investments Investment Narrative Recap

To own Clover Health, you have to believe its technology-enabled Medicare Advantage model can convert scale into durable profitability while managing medical costs and regulatory uncertainty. The latest move to raise 2026 revenue and GAAP net income guidance appears to support the near term profitability catalyst, but it does not remove the key risk that elevated medical and pharmacy utilization could still pressure margins if trends turn against the company.

The most relevant recent announcement is Clover Health’s upgraded 2026 outlook to US$2.92 billion to US$3.00 billion in total revenue and US$20 million to US$35 million in GAAP net income. Coming alongside a shift to positive net income in the first half of 2026, this guidance ties directly into the thesis that its differentiated, tech-driven care model and cost controls can improve margins, while still leaving exposure to regulatory and reimbursement changes.

Yet even as guidance improves, investors should be aware that elevated benefit expense ratios could still...

Read the full narrative on Clover Health Investments (it's free!)

Clover Health Investments’ narrative projects $4.0 billion revenue and $30.9 million earnings by 2029.

Uncover how Clover Health Investments' forecasts yield a $4.15 fair value, a 13% downside to its current price.

Exploring Other Perspectives

Before this earnings beat and guidance hike, the most optimistic analysts were already penciling in about US$4.1 billion of revenue and US$73.4 million of earnings by 2029, which shows just how much more upbeat their view is on Clover’s operating leverage and technology advantage compared with more cautious takes that focus on cost pressures and scale risks.

Explore 4 other fair value estimates on Clover Health Investments - why the stock might be worth 13% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Clover Health Investments research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Clover Health Investments research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Clover Health Investments' overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com